Amylyx Pharmaceuticals
PharmaCambridge, MA, United States, Massachusetts, United States
Score by Dimension
Score breakdown
Services Breadth
4/5Number of service categories this organization offers.
- ✓2 service categories listed
Advocacy Reach
How broadly this organization advocates and informs the ALS community.
- —Raises ALS awareness
- —Online information source
- —Publishes research / reports
- —International reach
- —Engages in policy / advocacy
Accessibility
5/5How easy it is for patients and families to reach this organization.
- ✓Has website
- ✓Has phone number
- ✓Has email
- ✓Has street address
- ✓Has map coordinates
Patient Support
Breadth of direct support offered to patients and families.
- —In-person support groups
- —Online support groups
- —Caregiver resources in services
- —Funds or provides home care
- —Children's resources
Data Completeness
5/5Percentage of profile fields with information.
- ✓Name
- ✓Type
- ✓Country
- ✓State / region
- ✓Address
- ✓Phone
- ✓Website
- ✓Mission
Network Connectivity
Connections to research consortia and ALS networks.
- —Part of a consortia
- —International reach
- —Publishes research
- —Maintains an ALS database
- —Mentions a known network (NEALS, ENCALS, TRICALS, etc.)
Contact
Mission
Cambridge, MA biopharmaceutical company. Relyvrio (AMX0035) was voluntarily withdrawn from the market in 2024 after the Phase 3 PHOENIX trial failed to demonstrate efficacy. No active ALS programs as of 2024; pipeline has shifted to other neurodegenerative and metabolic indications.
Community Reviews
Be the first to share your experience.
Is this your organization?
Claim this listing to verify your information and unlock premium features.
Subscribe to ALS Compass
Your weekly guide to ALS resources, research, and community.